The U.S. Food and Drug Administration plans to approve the use of unfinished COVID-19 vaccine
In an interview with the Financial Times, the US Food and Drug Administration Director Hahn said that the bureau is planning to approve the use of the unfinished third-stage COVID-19 vaccine, and the authorities are ready to approve the unfinished third-stage clinical use through emergency authorization. New coronary pneumonia vaccine tested. Currently, two vaccines in the United States have entered the third phase of testing, and there are still two more vaccines in mid-September. In order to confirm the safety of vaccines, pharmaceutical companies often recruit at least 30,000 people for testing. The market believes that skipping the third phase of clinical testing is not safe. But Hahn emphasized that the vaccine will only be authorized for use by specific groups, rather than fully approved for use. In other words, the vaccine is still far from reaching the stage of universal use.
The vice chairman of the U.S. Federal Reserve said that the unemployment rate alone is not enough to form conditions for raising interest rates.
Clarinda, vice chairman of the U.S. Federal Reserve, said when attending the economic forum that the unemployment rate alone has fallen, but inflation has not been maintained or is expected to rise above the target level of 2%. Under the new monetary policy framework of the Fed, it is still not enough Interest rate hike conditions. In addition, Clarinda does not believe that negative interest rates are an attractive policy. His comments suggest that the bureau does not tend to implement a negative interest policy, and under the new monetary policy framework, the threshold for the bureau to raise interest rates in the future will be quite high.
Z. com Bullion is an affiliate of GMO Financial Holdings, Inc., a Japanese listed group. The risk of loss in leveraged foreign exchange trading & margin trading can be substantial. Visit the company website to read full risk warning. https://bullion.z.com/en/about/legal/risk/